BD1047.2HBr

Research use only, not for human use.

BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors.

BD-1047 dihydrobromide is a selective functional antagonist of sigma receptors, shows antipsychotic activity in animal models predictive of efficacy in schizophrenia.

BD-1047 (dihydrobromide) prevents that Cutamesine reduces the cell death rate induced by light exposure in murine photoreceptor-derived 661w cells.BD-1047 (dihydrobromide) attenuates that Cutamesine reduces the mitochondrial damage and the elevated level of caspase 3/7 activity.

BD-1047 (dihydrobromide) (1-10 mg/kg; i.p.) decreases the Apomorphine (APO)-induced climbing behavior at the dose of 10 mg/kg in mice.BD-1047 (dihydrobromide) counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).BD-1047 (dihydrobromide) reduces the increasing expression of pNR1, and reverses the Sig-1 R agonists potentiated NMDA-induced pain behaviour and pNR1 immunoreactivity. Animal Model:Male Albino Swiss mice (50 days old, 25–28 g)Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg Administration:Intraperitoneal injection Result:Decreased the APO-induced climbing at the dose of 10 mg/kg in mice.

BD-1047 | BD 1047 | BD1047 | BD-1047 HBr

Autophagy

Sigma receptor

σ1

Neurological Disease

——

138356-21-5

437.04

C13H22Br2Cl2N2

>98% (HPLC)

Water: 10 mM

CN(CCN(CCC1=CC=C(Cl)C(Cl)=C1)C)C.[H]Br.[H]Br

N1-(3,4-dichlorophenethyl)-N1,N2,N2-trimethylethane-1,2-diamine dihydrobromide

(-20℃)

With Ice Pack

≥ 2 years